Inhibition of CDKs is an attractive approach to cancer therapy due to their vital role in cell growth and transcription. Pan-CDK inhibitors have shown some clinical benefit, and trials are ongoing. Selective CDK4 and CDK6 inhibitors have been licensed for the treatment of hormone responsive, RB-positive breast cancer in combination with antihormonal agents. Selective inhibitors of CDKs 5, 7, 8, 9 and 12 have been identified across a range of chemotypes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/fmc-2017-0246 | DOI Listing |
Publication Analysis
Top Keywords
cancer therapy
8
advances cdk
4
inhibitors
4
cdk inhibitors
4
inhibitors cancer
4
therapy inhibition
4
inhibition cdks
4
cdks attractive
4
attractive approach
4
approach cancer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!